Loading clinical trials...
Loading clinical trials...
A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)
Conditions
Interventions
ACP-01
Placebo
Locations
19
United States
UC Davis CTSC Clinical Research Center
Sacramento, California, United States
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, United States
University of Florida
Gainesville, Florida, United States
Clinovation Research, LLC
Miami, Florida, United States
Clinical Research of Central Florida
Winter Haven, Florida, United States
Decatur Memorial Hospital
Decatur, Illinois, United States
Start Date
August 1, 2014
Primary Completion Date
April 1, 2020
Completion Date
April 1, 2021
Last Updated
November 28, 2023
NCT03529019
NCT05854615
NCT06544135
NCT06066268
NCT05406622
NCT04054609
Lead Sponsor
Hemostemix
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions